3456 related articles for article (PubMed ID: 26850970)
41. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
43. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
Bukavina L; Luckenbaugh AN; Hofman MS; Hope T; Kamran SC; Murphy DG; Yamoah K; Ost P
Eur Urol; 2023 Jun; 83(6):521-533. PubMed ID: 36404204
[TBL] [Abstract][Full Text] [Related]
44. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
45. The future of choline PET in the era of prostate specific membrane antigen.
Evangelista L; Cuppari L; Zattoni F; Mansi L; Bombardieri E
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):19-28. PubMed ID: 29383928
[TBL] [Abstract][Full Text] [Related]
46. The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
Abrams-Pompe RS; Fanti S; Schoots IG; Moore CM; Turkbey B; Vickers AJ; Walz J; Steuber T; Eastham JA
Eur Urol Oncol; 2021 Jun; 4(3):370-395. PubMed ID: 33272865
[TBL] [Abstract][Full Text] [Related]
47. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
48. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
Treglia G; Ceriani L; Sadeghi R; Giovacchini G; Giovanella L
Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
[TBL] [Abstract][Full Text] [Related]
49. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.
Giovacchini G; Giovannini E; Leoncini R; Riondato M; Ciarmiello A
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1751-1776. PubMed ID: 28409220
[TBL] [Abstract][Full Text] [Related]
50. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
51. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
52. The role of
Kim SJ; Lee SW
Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
[TBL] [Abstract][Full Text] [Related]
53. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
54. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
55. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.
Oderda M; Joniau S; Palazzetti A; Falcone M; Melloni G; Van Den Bossche H; Deconinck S; Zattoni F; Karnes RJ; Gontero P
Eur Urol Focus; 2018 Mar; 4(2):288-293. PubMed ID: 30205893
[TBL] [Abstract][Full Text] [Related]
56. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
57. PET imaging for lymph node dissection in prostate cancer.
Incerti E; Mapelli P; Gianolli L; Picchio M
World J Urol; 2017 Apr; 35(4):507-515. PubMed ID: 27752756
[TBL] [Abstract][Full Text] [Related]
58. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
59. Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?
Vetrone L; Fortunati E; Castellucci P; Fanti S
Semin Nucl Med; 2024 Jan; 54(1):150-162. PubMed ID: 37394289
[TBL] [Abstract][Full Text] [Related]
60. The role of positron emission tomography/computed tomography imaging with radiolabeled choline analogues in prostate cancer.
Navarro-Pelayo Láinez MM; Rodríguez-Fernández A; Gómez-Río M; Vázquez-Alonso F; Cózar-Olmo JM; Llamas-Elvira JM
Actas Urol Esp; 2014 Nov; 38(9):613-21. PubMed ID: 24548475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
